Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM
Gateway
TOXNET
Consumer
Health
Clinical Alerts
ClinicalTrials.gov
PubMed
Central
Privacy Policy
|
 |
-
Drug-induced rash with
eosinophilia and systemic symptoms syndrome with bupropion
administration.
Bagshaw SM, Cload B, Gilmour J,
Leung ST, Bowen TJ.
Department of Medicine, Foothills Medical
Centre, University of Calgary, Calgary, Alberta,
Canada.
BACKGROUND: Sustained-release bupropion is commonly used
for the symptomatic relief of depressive illness and as an adjuvant in
smoking cessation therapy. OBJECTIVE: To report a case of
bupropion-induced drug rash with eosinophilia and systemic symptoms
syndrome, including acute hepatitis, obstructive lung disease, and
myositis. METHODS: After the patient discontinued use of bupropion,
serologic tests, muscle biopsies, pulmonary function tests, a chest
x-ray examination, venous Doppler ultrasounds, and an electrocardiogram
were performed. RESULTS: On discontinuation of bupropion and prolonged
systemic corticosteroid therapy, there was complete resolution of
symptoms. CONCLUSIONS: To our knowledge, this is the first reported case
of drug rash with eosinophilia and systemic symptoms syndrome induced by
bupropion therapy. We report this case to notify clinicians of the
potential serious multisystem complications that can occur with
sustained-release bupropion therapy.
Publication Types:
PMID: 12775141 [PubMed - indexed for
MEDLINE]
|